Genetic in origin
DMD is usually inherited in an X-linked pattern, though a genetic change can also occur for the first time in a family.
Clear, compassionate information for families, caregivers, and anyone learning about Duchenne (DMD)—from early signs to coordinated lifelong care.
Duchenne muscular dystrophy (DMD) is a genetic condition that causes progressive muscle weakness. It occurs when changes in the DMD gene prevent the body from making enough functional dystrophin, a protein that helps protect muscle cells.
DMD is usually inherited in an X-linked pattern, though a genetic change can also occur for the first time in a family.
Muscle weakness typically begins in early childhood and can eventually affect mobility, breathing, and heart function.
Multidisciplinary care, supportive therapies, and mutation-specific treatment options can help address complications and quality of life.
Signs often appear in the preschool years. Not every child has every symptom, and other conditions can cause similar changes.
Concerned? Ask a clinician about an evaluation. A blood creatine kinase (CK) test is often an early step.
A diagnosis typically combines a clinical evaluation with laboratory testing and genetic confirmation.
A clinician reviews muscle strength, developmental history, family history, and symptoms.
CK is often markedly elevated when muscle fibers are damaged. A high CK result alone does not confirm DMD.
Testing for changes in the DMD gene can confirm the diagnosis and help determine eligibility for certain therapies or trials.
Genetic counseling may help families understand inheritance, carrier testing, and reproductive options.
A specialist-led care team can plan ahead, track changes, and support independence and participation in daily life.
Physical and occupational therapy, stretching, assistive technology, and orthopedic monitoring can support function and comfort.
Regular cardiac and respiratory evaluations help detect changes early and guide supportive treatments.
Corticosteroid-based treatments and some gene- or mutation-targeted therapies may be considered based on individual circumstances, risks, and current approvals.
Monitoring growth, bone health, swallowing, and nutrition is an important part of ongoing care.
Educational accommodations, mental health support, and family counseling can help meet changing needs.
Transition planning includes adult specialists, accessible housing, education, work, and self-directed decision-making.
No. Both involve the DMD gene, but Becker muscular dystrophy usually allows some functional dystrophin and often follows a slower course.
Yes. Although DMD primarily affects boys, some girls and women with DMD gene variants can have muscle or heart symptoms and should receive appropriate evaluation.
There is currently no established cure for DMD. Treatments and supportive care can improve outcomes, and research continues.
Some therapies and research studies target particular genetic variants. A genetic report helps specialists assess which options may be relevant.
These organizations offer clinical education, care guidance, research updates, and support for families.